00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
18:19 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays, diagnostic assays; plasma markers Circulating CD4 + T cells specific for full-length C-peptide could be used for early diagnosis of Type I diabetes. In peripheral blood samples from patients with recent-onset Type...
22:23 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Cancer antigens from RNA edits

A team from Immatics Biotechnologies GmbH and University of Texas MD Anderson Cancer Center has shown that cancer antigens generated via post-transcriptional RNA editing could further broaden the target space for immunotherapies. The study ,...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
17:13 , Aug 23, 2018 |  BC Innovations  |  Translation in Brief

The self-destructing pancreas

A pair of independent papers from researchers from Washington University School of Medicine in St. Louis and Institut National de la Santé et de la Recherche Médicale (INSERM) illustrate how pancreatic β cells may contribute...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Nohla adds $11M to series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised an additional $11 million on June 11 in the second close of a series B financing, bringing the round’s total to $56 million. New investors...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications. Immatics will receive $54 million up front and...
21:01 , Jul 12, 2018 |  BC Extra  |  Company News

Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications. Immatics will receive $54 million up front and...
16:42 , Jul 6, 2018 |  BC Week In Review  |  Company News

Athenex Announces Two China Deals Plus $100M Raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy July 2 that also saw the biotech raise $100 million in equity and debt. The company said it is forming...
23:18 , Jul 2, 2018 |  BC Extra  |  Company News

Athenex announces two China deals plus $100M raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy Monday that also saw the biotech raise $100 million in equity and debt. The company said it is forming a...